Androgen receptor signaling in prostate cancer and therapeutic strategies

Medicine and Dentistry

• Prostate Cancer 100%
• Androgen Receptor 100%
• Cell Signaling Pathway 18%
• Androgen 18%
• Clinical Trial 9%
• DNA Repair 9%
• Androgen Synthesis 9%
• Abiraterone 9%
• Androgen Receptor Antagonist 9%
• MAPK Signaling 9%
• Darolutamide 9%
• Apalutamide 9%
• PI3K/AKT/mTOR Pathway 9%
• Drug Resistance 9%
• Wnt Signaling 9%
• Enzalutamide 9%
• Glucocorticoid Receptor 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Prostate Cancer 100%
• Androgen Receptor 100%
• Androgen 27%
• Clinical Trial 9%
• Enzalutamide 9%
• Abiraterone 9%
• Androgen Receptor Antagonist 9%
• Darolutamide 9%
• Apalutamide 9%
• Glucocorticoid Receptor 9%
• Drug Resistance 9%
• Protein Kinase B 9%

Biochemistry, Genetics and Molecular Biology

• Androgen Receptor 100%
• Clinical Trial 8%
• Wnt Signaling Pathway 8%
• PI3K/AKT/mTOR Pathway 8%
• DNA Repair 8%
• Receptor Antagonist 8%
• MAPK Signaling 8%
• Androgen Synthesis 8%
• Drug Resistance 8%
• Glucocorticoid Receptor 8%
• Enzalutamide 8%